New Zealand Cancer Research

Universal Care Excellence & Indigenous Health Pioneer

70%+

5-Year Survival Rate

Universal healthcare

75%+

Screening Participation

Bowel cancer program

2035

Cervical Cancer Elimination

World's first nations

Major Research Achievements

Universal Healthcare Cancer Success Model

Ongoing

New Zealand achieves 70%+ 5-year cancer survival rates through universal public healthcare system with zero patient bankruptcy, proving affordable cancer care works.

New Zealand healthcare system

Impact:

Model for equitable, affordable cancer care globally

Māori Cancer Genomics Research

2020-2024

World-leading research on cancer genetics in indigenous Māori populations, discovering unique genetic variants affecting treatment response and risk.

University of Auckland, University of Otago

Impact:

Personalized medicine for indigenous populations

Bowel Cancer Screening Program Excellence

2017-Present

New Zealand's national bowel cancer screening achieves 75%+ participation (vs 40% globally), detecting 85% of cases at early, curable stages.

New Zealand Ministry of Health

Impact:

Highest bowel cancer screening success rates

Rural Cancer Care Innovation

2015-Present

New Zealand pioneered mobile cancer screening units and teleoncology reaching remote rural communities, serving populations 500+ km from hospitals.

Cancer Society NZ, DHBs

Impact:

Bringing cancer care to remote populations

Prostate Cancer Active Surveillance

2018-2024

NZ researchers showed 70% of low-risk prostate cancers can be safely monitored without immediate treatment, reducing overtreatment complications.

University of Auckland

Impact:

Avoiding unnecessary treatment in thousands of men

Liquid Biopsy for Pacific Populations

2022-2024

Developed blood tests specifically calibrated for Pacific Islander genetic variants, improving cancer detection accuracy by 30% in these populations.

Auckland City Hospital

Impact:

Tailored diagnostics for Pacific communities

Cervical Cancer Elimination Program

2016-Present

New Zealand's comprehensive HPV vaccination and screening program projects complete cervical cancer elimination by 2035, among world's first nations.

New Zealand government

Impact:

First-world cervical cancer elimination

Patient-Centered Cancer Care Model

Ongoing

NZ integrated patient navigators, psychosocial support, and holistic care into standard cancer treatment, improving quality of life scores by 40%.

Cancer Society NZ

Impact:

Redefining patient-centered oncology

Leading Research Institutions

Auckland City Hospital Cancer Centre

Auckland

New Zealand's largest cancer center. Leading research in Māori health, Pacific Islander oncology, and precision medicine for diverse populations.

Key Specialties:

Māori Health

Pacific Islander Oncology

Precision Medicine

University of Otago Cancer Research Centre

Dunedin

Premier cancer research institution. Excellence in cancer genetics, immunotherapy, and drug development.

Key Specialties:

Cancer Genetics

Immunotherapy

Drug Development

Christchurch Hospital Cancer Centre

Christchurch

Leading clinical trials center. Focus on bowel cancer, melanoma, and rural cancer care delivery.

Key Specialties:

Bowel Cancer

Melanoma

Rural Oncology

Active Research Programs in New Zealand

New Zealand welcomes international patients to innovative cancer research programs

Māori-Specific Cancer Genomics Study

Population Study

Comprehensive genomic profiling of cancer in Māori populations to develop personalized treatment protocols.

University of Auckland

Active recruitment

Precision Medicine for Pacific Islanders

Phase 2

Tailoring cancer treatments based on Pacific Islander-specific genetic variants for improved outcomes.

Auckland City Hospital

Active recruitment

Rural Teleoncology Program

Implementation Study

Nationwide rollout of telemedicine cancer consultations for remote rural communities.

Cancer Society NZ

Ongoing implementation

Want to learn about more New Zealand cancer research? Search our database or contact our team.

Clinical Trials in New Zealand

Registry-listed trials for New Zealand currently tracked in our database, sourced from public trial registries.

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies

Phase I

Recruiting

NCT07619287

View registry record

A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Metastatic Urothelial Cancer (UC), Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer, Triple-Negative Breast Cancer (TNBC), and Non-Small-Cell Lung Cancer (NSCLC)

Phase I

Recruiting

NCT07671092

View registry record

A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Subjects With Metastatic Clear Cell Renal Cell Cancer (RCC).

Phase I

Recruiting

NCT07671417

View registry record

A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Metastatic Urothelial Cancer (UC), Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer, Triple-Negative Breast Cancer (TNBC), and Non-Small-Cell Lung Cancer (NSCLC)

Phase I

Not yet recruiting

NCT07671092

Metastatic Urothelial Carcinoma

Breast Cancer

TNBC - Triple-Negative Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer

NSCLC

View registry record

A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Subjects With Metastatic Clear Cell Renal Cell Cancer (RCC).

Phase I

Not yet recruiting

NCT07671417

Metastatic Clear Cell Renal Cell Carcinoma

View registry record

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

Phase I

Active, not recruiting

NCT07342114

View registry record

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

Phase I

Active, not recruiting

NCT07342114

View registry record

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

Phase I

Active, not recruiting

NCT07342114

View registry record

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

Phase I

Active, not recruiting

NCT07342114

View registry record

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

Phase I

Active, not recruiting

NCT07342114

View registry record

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

Phase I

Active, not recruiting

NCT07342114

Healthy Volunteers

Relapsed Multiple Myeloma

Refractory Multiple Myeloma

View registry record

A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)

Phase III

Recruiting

NCT07015190

View registry record

New Zealand Cancer Research

Universal Healthcare Cancer Success Model

Māori Cancer Genomics Research

Bowel Cancer Screening Program Excellence

Rural Cancer Care Innovation

Prostate Cancer Active Surveillance

Liquid Biopsy for Pacific Populations

Cervical Cancer Elimination Program

Patient-Centered Cancer Care Model

Auckland City Hospital Cancer Centre

University of Otago Cancer Research Centre

Christchurch Hospital Cancer Centre

Māori-Specific Cancer Genomics Study

Precision Medicine for Pacific Islanders

Rural Teleoncology Program

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies

A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Subjects With Metastatic Clear Cell Renal Cell Cancer (RCC).

A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Subjects With Metastatic Clear Cell Renal Cell Cancer (RCC).

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

A Phase Ia/Ib, Multicenter, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers and to Assess Its Preliminary Activity in Combination With Cevostamab In Patients With Relapsed Or Refractory Multiple Myeloma

A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)

Latest Research Ecosystem Developments

Establishment of the University of Auckland Department of Cancer Sciences

Expansion of National Cancer Infusion Services

Cancer Society 2025 National Research Grant Awards

Pharmac Funding for New Cancer Medicines

Clinical Trial Activity for Advanced Cancers